Department of Pharmaceutical Sciences, North Dakota State University, Fargo, ND, USA.
Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA.
Mol Cell Endocrinol. 2018 Nov 15;476:37-47. doi: 10.1016/j.mce.2018.04.007. Epub 2018 Apr 20.
Airway smooth muscle (ASM) cell hyperplasia driven by persistent inflammation is a hallmark feature of remodeling in asthma. Sex steroid signaling in the lungs is of considerable interest, given epidemiological data showing more asthma in pre-menopausal women and aging men. Our previous studies demonstrated that estrogen receptor (ER) expression increases in asthmatic human ASM; however, very limited data are available regarding differential roles of ERα vs. ERβ isoforms in human ASM cell proliferation. In this study, we evaluated the effect of selective ERα and ERβ modulators on platelet-derived growth factor (PDGF)-stimulated ASM proliferation and the mechanisms involved. Asthmatic and non-asthmatic primary human ASM cells were treated with PDGF, 17β-estradiol, ERα-agonist and/or ERβ-agonist and/or G-protein-coupled estrogen receptor 30 (GPR30/GPER) agonist and proliferation was measured using MTT and CyQuant assays followed by cell cycle analysis. Transfection of small interfering RNA (siRNA) ERα and ERβ significantly altered the human ASM proliferation. The specificity of siRNA transfection was confirmed by Western blot analysis. Gene and protein expression of cell cycle-related antigens (PCNA and Ki67) and C/EBP were measured by RT-PCR and Western analysis, along with cell signaling proteins. PDGF significantly increased ASM proliferation in non-asthmatic and asthmatic cells. Treatment with PPT showed no significant effect on PDGF-induced proliferation, whereas WAY interestingly suppressed proliferation via inhibition of ERK1/2, Akt, and p38 signaling. PDGF-induced gene expression of PCNA, Ki67 and C/EBP in human ASM was significantly lower in cells pre-treated with WAY. Furthermore, WAY also inhibited PDGF-activated PCNA, C/EBP, cyclin-D1, and cyclin-E. Overall, we demonstrate ER isoform-specific signaling in the context of ASM proliferation. Activation of ERβ can diminish remodeling in human ASM by inhibiting pro-proliferative signaling pathways, and may point to a novel perception for blunting airway remodeling.
气道平滑肌 (ASM) 细胞的增生是哮喘重塑的一个主要特征,这种增生由持续的炎症所驱动。鉴于流行病学数据显示,绝经前女性和老年男性的哮喘发病率更高,因此肺部的性激素信号很重要。我们之前的研究表明,雌激素受体 (ER) 在哮喘患者的气道平滑肌中表达增加;然而,关于 ERα 与 ERβ 同工型在人 ASM 细胞增殖中的差异作用,数据非常有限。在这项研究中,我们评估了选择性 ERα 和 ERβ 调节剂对血小板衍生生长因子 (PDGF) 刺激的 ASM 增殖的影响及其相关机制。用 PDGF、17β-雌二醇、ERα 激动剂和/或 ERβ 激动剂和/或 G 蛋白偶联雌激素受体 30 (GPR30/GPER) 激动剂处理哮喘和非哮喘的原代人 ASM 细胞,并通过 MTT 和 CyQuant 测定法测量增殖,随后进行细胞周期分析。转染小干扰 RNA (siRNA) ERα 和 ERβ 显著改变了人 ASM 的增殖。通过 Western blot 分析证实了 siRNA 转染的特异性。通过 RT-PCR 和 Western 分析以及细胞信号蛋白,测量细胞周期相关抗原 (PCNA 和 Ki67) 和 C/EBP 的基因和蛋白表达。PDGF 显著增加了非哮喘和哮喘细胞中的 ASM 增殖。用 PPT 处理对 PDGF 诱导的增殖没有显著影响,而 WAY 则通过抑制 ERK1/2、Akt 和 p38 信号通路,有趣地抑制了增殖。WAY 预处理的细胞中,PDGF 诱导的人 ASM 中 PCNA、Ki67 和 C/EBP 的基因表达显著降低。此外,WAY 还抑制了 PDGF 激活的 PCNA、C/EBP、细胞周期蛋白 D1 和细胞周期蛋白 E。总的来说,我们证明了 ER 同工型在 ASM 增殖方面的信号特异性。ERβ 的激活可以通过抑制促增殖信号通路来减少人 ASM 的重塑,并可能为抑制气道重塑提供新的认识。